CSE$NVO

Novo Nordisk B A/S · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Novo Nordisk Q4 2024: DKK 85.7B sales, DKK 28.2B net profit on 30% revenue growth

Novo Nordisk reported fourth quarter and full year 2024 results on February 5, 2025. Q4 net sales rose 30% to DKK 85,683 million with operating profit up 37% to DKK 36,737 million. Net profit for the quarter was DKK 28,230 million versus DKK 21,963 million in Q4 2023, and diluted EPS was DKK 6.34. Full year net sales grew 25% to DKK 290,403 million and full year net profit reached DKK 100,988 million with diluted EPS of DKK 22.63. Obesity care sales grew 56% in 2024 to DKK 65.1 billion. For 2025, management expects sales growth of 16–24% at constant exchange rates and operating profit growth of 19–27% at CER.

  • Q4 net sales of DKK 85.7B up 30% YoY; operating profit up 37% to DKK 36.7B
  • Q4 net profit of DKK 28.2B beat expectations; diluted EPS DKK 6.34
  • Full year sales reached DKK 290.4B (+25%); obesity care sales DKK 65.1B (+56%)
  • Completed acquisition of three Catalent manufacturing sites in December 2024
  • 2025 outlook: 16–24% sales growth and 19–27% operating profit growth at CER

Headline financials

Total Revenue

kr85.7B

No prior period
EPS (adj)

kr6.34

No prior period
Q4 operating margin

42.9%

No prior period
Wegovy Q4 sales (DKK)

kr19.9B

No prior period
Net Income

kr28.2B

No prior period
Operating Income

kr36.7B

No prior period

Revenue & EPS history

Novo Nordisk · Revenue · Quarterly

kr85.7B

Q4 2024
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Novo Nordisk · kr272B total across 1 segment · Q4 2024

  • Diabetes and Obesity care
    kr272B

Forward guidance

2025 sales growth expected at 16–24% CER and operating profit growth at 19–27% CER.

Tailwinds

  • GLP-1 demand remains strong
  • Pipeline progress on CagriSema and amycretin

Headwinds

  • Guidance reflects intensifying competition and pricing pressure

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+31.7%

Avg return

Earnings day

+14.7%

Avg return

5 days after

+14.1%

Avg return

30 days after

50%

24 / 48 earnings

Positive

+597.3%

Q1 2025

Best reaction

-13.9%

Q2 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+556.0%+569.8%+533.1%
Q3 2025-4.4%-4.8%-0.8%
Q1 2025+597.3%+3.0%+9.0%
Q4 2024+2.2%+1.6%+5.5%
Q3 2024-0.2%-0.9%+0.6%
Q2 2024-2.2%-0.2%+0.8%
Q1 2024-3.9%-1.5%+4.7%
Q3 2023+1.6%+4.1%+2.8%
Q2 2023-2.9%-1.3%+4.2%
Q1 2023-3.7%+0.5%-6.3%
Q4 2022-5.1%-0.5%+4.4%
Q3 2022+2.4%+8.1%+19.2%
Q2 2022-9.1%-10.5%-10.7%
Q1 2022+3.7%+3.4%-2.2%
Q4 2021+4.9%-0.8%+1.5%
Q3 2021+3.9%+4.2%-2.7%
Q2 2021+0.3%+1.9%+2.7%
Q1 2021+2.7%+2.9%+9.2%
Q4 2020+1.1%-0.1%-1.9%
Q3 2020-5.1%+5.5%+1.8%
Q2 2020-3.3%+0.2%+0.0%
Q1 2020-0.3%+1.3%+2.2%
Q4 2019+4.4%+3.3%+1.6%
Q3 2019+2.3%+2.7%+1.7%
Q2 2019+3.9%+3.2%+3.7%
Q1 2019-2.8%-0.9%-3.4%
Q4 2018+2.7%+3.5%+5.5%
Q3 2018+3.3%-0.1%+8.0%
Q2 2018-5.4%-5.8%-4.5%
Q1 2018+6.9%+0.2%+0.2%
Q4 2017-9.1%-10.8%-8.6%
Q3 2017-0.2%-0.2%+4.4%
Q2 2017+0.0%-2.1%+2.6%
Q1 2017+6.6%+2.0%+11.2%
Q4 2016-8.4%-9.0%-5.5%
Q3 2016-13.6%-13.9%-21.6%
Q2 2016-13.9%+0.6%-20.1%
Q1 2016-1.2%+0.9%-14.4%
Q4 2015+5.0%
Q3 2015-6.0%
Q2 2015-4.5%
Q1 2015+2.8%
Q4 2014-2.8%
Q3 2014+5.7%
Q2 2014-3.5%
Q1 2014+2.5%
Q4 2013+9.5%
Q3 2013+400.0%
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro